Literature DB >> 31222884

Chronotherapy as a potential approach to hypertensive patients with elevated heart rate?

Fedor Simko1,2,3, Tomas Baka1.   

Abstract

Entities:  

Keywords:  chronotherapy; heart rate; hypertension; ivabradine; melatonin

Year:  2019        PMID： 31222884      PMCID： PMC6624435          DOI： 10.1111/bcp.14020

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.

Authors:  Robinson Joannides; Nicholas Moore; Michaela Iacob; Patricia Compagnon; Guy Lerebours; Jean-François Menard; Christian Thuillez
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

2.  Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  J Am Coll Cardiol       Date:  2011-09-06       Impact factor: 24.094

3.  Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension.

Authors:  Paolo Palatini; Enrico Agabiti Rosei; Edoardo Casiglia; John Chalmers; Roberto Ferrari; Guido Grassi; Teruo Inoue; Bojan Jelakovic; Magnus T Jensen; Stevo Julius; Sverre E Kjeldsen; Giuseppe Mancia; Gianfranco Parati; Paolo Pauletto; Andrea Stella; Alberto Zanchetti
Journal:  J Hypertens       Date:  2016-05       Impact factor: 4.844

Review 4.  Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses.

Authors:  Claudio Borghi; Arrigo F G Cicero
Journal:  Br J Clin Pharmacol       Date:  2016-03-15       Impact factor: 4.335

5.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

Review 6.  Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.

Authors:  Jeffrey S Borer; Prakash C Deedwania; Jae B Kim; Michael Böhm
Journal:  Am J Cardiol       Date:  2016-09-15       Impact factor: 2.778

7.  Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.

Authors:  Kim Fox; Ian Ford; Philippe Gabriel Steg; Jean-Claude Tardif; Michal Tendera; Roberto Ferrari
Journal:  Eur Heart J       Date:  2015-09-17       Impact factor: 29.983

Review 8.  Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review.

Authors:  Fedor Simko; Tomas Baka; Ludovit Paulis; Russel J Reiter
Journal:  J Pineal Res       Date:  2016-07-01       Impact factor: 13.007

9.  Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention.

Authors:  Ramón C Hermida; Juan J Crespo; Alfonso Otero; Manuel Domínguez-Sardiña; Ana Moyá; María T Ríos; María C Castiñeira; Pedro A Callejas; Lorenzo Pousa; Elvira Sineiro; José L Salgado; Carmen Durán; Juan J Sánchez; José R Fernández; Artemio Mojón; Diana E Ayala
Journal:  Eur Heart J       Date:  2018-12-14       Impact factor: 29.983

10.  Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study.

Authors:  David A Rorie; Amy Rogers; Isla S Mackenzie; Ian Ford; David J Webb; Bryan Willams; Morris Brown; Neil Poulter; Evelyn Findlay; Wendy Saywood; Thomas M MacDonald
Journal:  BMJ Open       Date:  2016-02-09       Impact factor: 2.692
View more
  4 in total

1.  Ivabradine and Blood Pressure Reduction: Underlying Pleiotropic Mechanisms and Clinical Implications.

Authors:  Fedor Simko; Tomas Baka
Journal:  Front Cardiovasc Med       Date:  2021-02-10

2.  Chronotherapy of cardiovascular pathologies: a hopeful strategy.

Authors:  Fedor Simko; Tomas Baka
Journal:  Ther Adv Chronic Dis       Date:  2022-04-18       Impact factor: 4.970

Review 3.  Cardiovascular therapeutics: A new potential for anxiety treatment?

Authors:  Kristina Repova; Silvia Aziriova; Kristina Krajcirovicova; Fedor Simko
Journal:  Med Res Rev       Date:  2022-01-06       Impact factor: 12.388

4.  Circadian Effects of Drug Responses.

Authors:  Yaakov Nahmias; Ioannis P Androulakis
Journal:  Annu Rev Biomed Eng       Date:  2021-03-31       Impact factor: 9.590
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.